Age, Biography and Wiki
Randal J. Kirk is a 66-year-old American biotech investor and entrepreneur. He is the founder and senior managing director of Third Security, LLC, a venture capital firm that invests in biotechnology and healthcare companies. He is also the CEO of Intrexon Corporation, a synthetic biology company. Kirk has a net worth of $2.5 billion, according to Forbes. He earned his wealth through his investments in biotechnology and healthcare companies. He has also served as a director of several companies, including the biopharmaceutical company Celgene Corporation. Kirk is a graduate of the University of Virginia, where he earned a Bachelor of Arts degree in economics. He also holds a Master of Business Administration degree from the University of Virginia's Darden School of Business. Kirk is married to his wife, Susan, and they have two children. He is an avid collector of vintage cars and enjoys playing golf.
| Popular As | N/A |
| Occupation | Biotech investor; CEO of Intrexon Corporation; founder and senior managing director of Third Security, LLC |
| Age | 69 years old |
| Zodiac Sign | Pisces |
| Born | 1 March, 1954 |
| Birthday | 1 March |
| Birthplace | Pleasanton, California, U.S. |
| Nationality | U.S. |
We recommend you to check the complete list of Famous People born on 1 March. He is a member of famous with the age 69 years old group. He one of the Richest who was born in U.S..
Randal J. Kirk Height, Weight & Measurements
At 69 years old, Randal J. Kirk height not available right now. We will update Randal J. Kirk's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status | |
|---|---|
| Height | Not Available |
| Weight | Not Available |
| Body Measurements | Not Available |
| Eye Color | Not Available |
| Hair Color | Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family | |
|---|---|
| Parents | Not Available |
| Wife | Not Available |
| Sibling | Not Available |
| Children | 4 |
Randal J. Kirk Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is Randal J. Kirk worth at the age of 69 years old? Randal J. Kirk’s income source is mostly from being a successful . He is from U.S.. We have estimated Randal J. Kirk's net worth , money, salary, income, and assets.
| Net worth | US $ 3.3 billion (est. in January 2017) |
| Salary in 2023 | Under Review |
| Net Worth in 2022 | Pending |
| Salary in 2022 | Under Review |
| House | Not Available |
| Cars | Not Available |
| Source of Income |
Randal J. Kirk Social Network
Timeline
Following the sale of General Injectables and Vaccines, Kirk donated $1 million to Radford University, creating the Zylphia Shu-En Kirk Endowment named after his daughter. Kirk has served on the board of directors of the Radford University Foundation and the school's board of visitors. Kirk was a member of University of Virginia's board of visitors from 2009 to 2012.
Kirk has also donated substantially to political causes. He considers himself a political independent, and has supported both Republicans and Democrats. He has been especially involved in Virginia politics, donating $1.8 million to candidates for state office, including $200,000 to Terry McAuliffe's 2009 Virginia gubernatorial election. Since 1994 he has donated $183,250 in federal elections.
Kirk has been profiled by SynBioBeta and Forbes. In 2008, Virginia Gov. Tim Kaine named Kirk Virginia's Outstanding Industrialist for the Year. He has spoken at the SynBioBeta Conference, BioFlorida, Klick Ideas Exchange and was a Borlaug Dialogue Speaker at the World Food Prize.
Kirk became involved with biotechnology company Intrexon in the 2000s. He was named chairman of its board in 2008 and became CEO in 2009. Kirk took Intrexon public in 2013, taking the company's market cap to $2.5 billion with the IPO.
In 1999, Kirk founded the life-sciences investment firm Third Security, LLC, where he is senior managing director, CEO and chairman. From 2000 to 2002, Kirk served as a member of the board of directors for Scios, Inc., a maker of heart disease medication that later sold to Johnson & Johnson for $2.4 billion. Kirk also became the majority stock holder and chairman of Newton, Massachusetts-based pharmaceutical company Clinical Data, Inc. In 2011, shortly after Clinical Data's drug Viibryd received regulatory approval, Forest Laboratories bought Clinical Data for $1.2 billion.
In 1996, Kirk founded New River Pharmaceuticals, where he served as chairman and CEO and took the company public in 2004. The developer of attention-deficit drug Vyvanse, New River would prove to be Kirk's single biggest payoff when he sold the company to Shire in 2007 for $2.6 billion, making over a $1 billion for Kirk himself.
Kirk was admitted to the bar in 1980, becoming the only attorney in Bland, Virginia, and began a practice he ran until 1990. In 1983, he partnered with Bland County pharmacist John Gregory to found the next-day pharmaceutical distributor General Injectables and Vaccines. Kirk and his partners would go on to sell the business to Henry Schein, Inc. for $65 million in 1998.
Randal J. Kirk was born in Pleasanton, California. The son of a U.S. Air Force master sergeant, Kirk and his family moved from California to Texas before settling in Virginia. Kirk graduated from Pulaski High School in Pulaski County, Virginia. Following high school, Kirk worked selling cars and motorcycles, and enrolled part-time at Radford University to study business. He earned a bachelor's degree in Economics at Radford in 1976, followed by a Juris Doctor at the University of Virginia in 1979.
Randal J. Kirk (born March 1, 1954) is an American businessman and investor in pharmaceuticals and biotechnology. Kirk is the chairman and chief executive officer of Intrexon (NYSE: XON), a biotechnology company. Kirk started as a lawyer, but is best known for his investments in pharmaceutical and biotech companies. In addition to high-profile sales of New River Pharmaceuticals, Inc., and Clinical Data, Inc, Kirk also founded investment firm Third Security, LLC, and has held board seats with biotech companies, such as Scios, Inc., and ZIOPHARM Oncology. He is a billionaire and is listed on the Forbes 400.
